Trial reportThe Journal of allergy and clinical immunology2019
Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Trial report in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2024Trial
- Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.The Journal of allergy and clinical immunology · 2023Trial
- Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.Allergy · 2022Trial
- Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.The Journal of allergy and clinical immunology · 2021Trial
- Importance of B cells (Review).International journal of molecular medicine · 2026Review
- Cpg boosts peptide-based oral immunotherapy in mice with peanut allergy.Frontiers in allergy · 2026Article
- Considerations for biologics as front-line treatment in allergic diseases.Frontiers in immunology · 2025Review
- Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons.Frontiers in immunology · 2025Review
- Scientific developments in understanding food allergy prevention, diagnosis, and treatment.Frontiers in immunology · 2025Review
- Emerging diagnostic and therapeutic opportunities in food allergy.Frontiers in immunology · 2025Review
- Recent advances in food allergen immunotherapy.Clinical and experimental pediatrics · 2024Article
- A review of sublingual immunotherapy for treatment of peanut allergy.Journal of food allergy · 2024Article
- Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- The Future of Food Allergy Management: Advancements in Therapies.Current allergy and asthma reports · 2024Review
- Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.Medicina (Kaunas, Lithuania) · 2024Review
- Optimal period for achieving sustained unresponsiveness in peanut oral immunotherapy.Asia Pacific allergy · 2023Article
- A case of food and aeroallergen sublingual immunotherapy inducing eosinophilic esophagitis.The journal of allergy and clinical immunology. Global · 2023Article
- Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand.Frontiers in allergy · 2023Review
- Update on clinical research for food allergy treatment.Frontiers in allergy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPeanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment.
objectiveWe sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy.
methodsChildren with peanut allergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure.
resultsThirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG
conclusionExtended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanut allergy that was balanced with ease of administration and a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.